FOSCARNET SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for foscarnet sodium and what is the scope of patent protection?
Foscarnet sodium
is the generic ingredient in two branded drugs marketed by Amneal, Avet Lifesciences, Beijing, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, and Clinigen Hlthcare, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for foscarnet sodium. Eight suppliers are listed for this compound.
Summary for FOSCARNET SODIUM
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 7 |
| NDAs: | 7 |
| Drug Master File Entries: | 7 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 24 |
| Patent Applications: | 6 |
| What excipients (inactive ingredients) are in FOSCARNET SODIUM? | FOSCARNET SODIUM excipients list |
| DailyMed Link: | FOSCARNET SODIUM at DailyMed |
Recent Clinical Trials for FOSCARNET SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Peking University People's Hospital | Phase 4 |
| Cttq | Phase 4 |
| City of Hope Medical Center |
Pharmacology for FOSCARNET SODIUM
| Drug Class | Pyrophosphate Analog DNA Polymerase Inhibitor |
| Mechanism of Action | Chelating Activity DNA Polymerase Inhibitors |
Medical Subject Heading (MeSH) Categories for FOSCARNET SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for FOSCARNET SODIUM
US Patents and Regulatory Information for FOSCARNET SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avet Lifesciences | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213807-001 | Jun 5, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 077174-001 | May 31, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Clinigen Hlthcare | FOSCAVIR | foscarnet sodium | INJECTABLE;INJECTION | 020068-001 | Sep 27, 1991 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Beijing | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213987-001 | Nov 29, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Amneal | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 216602-001 | Mar 1, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Gland Pharma Ltd | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213001-001 | Apr 21, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FOSCARNET SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Clinigen Hlthcare | FOSCAVIR | foscarnet sodium | INJECTABLE;INJECTION | 020068-001 | Sep 27, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Clinigen Hlthcare | FOSCAVIR | foscarnet sodium | INJECTABLE;INJECTION | 020068-001 | Sep 27, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Clinigen Hlthcare | FOSCAVIR | foscarnet sodium | INJECTABLE;INJECTION | 020068-001 | Sep 27, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Clinigen Hlthcare | FOSCAVIR | foscarnet sodium | INJECTABLE;INJECTION | 020068-001 | Sep 27, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
